Quanterix Q4 2020 Earnings Report
Key Takeaways
Quanterix reported Q4 GAAP revenue of $26.1 million and non-GAAP revenue of $21.6 million, representing a 36% increase compared to the previous year. The company is focusing on the long-term impact of COVID-19 on human health and scaling its operations to meet the growing demand for ultra-sensitive protein analytical tools.
Q4 GAAP revenue including Grant Revenue was $26.1M.
Q4 non-GAAP revenue was $21.6M, a 36% increase versus prior year.
The company is addressing the pandemic crisis and advances in Alzheimer's therapies.
Quanterix is scaling to support this unprecedented opportunity in precision health.
Quanterix
Quanterix
Forward Guidance
Quanterix is entering 2021 on strong footing, scaling to support the unprecedented opportunity in precision health, and focusing on analytical tools to support disease studies, diagnostics, and drug development.